Short Interest in Pluri Inc. (NASDAQ:PLUR) Expands By 176.6%

Pluri Inc. (NASDAQ:PLUR) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 35,400 shares, a growth of 176.6% from the March 31st total of 12,800 shares. Based on an average daily trading volume, of 29,700 shares, the short-interest ratio is presently 1.2 days. Approximately 0.9% of the company’s stock are short sold.

Institutional Trading of Pluri

A hedge fund recently raised its stake in Pluri stock. Values First Advisors Inc. lifted its position in Pluri Inc. (NASDAQ:PLUR) by 168.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,547 shares of the company’s stock after purchasing an additional 85,037 shares during the quarter. Values First Advisors Inc. owned 0.33% of Pluri worth $81,000 at the end of the most recent reporting period. 16.59% of the stock is owned by institutional investors and hedge funds.

Pluri Stock Performance

Shares of NASDAQ:PLUR traded up $0.46 during trading on Friday, reaching $5.36. The stock had a trading volume of 6,889 shares, compared to its average volume of 55,723. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 3.69. The stock has a fifty day simple moving average of $6.40 and a two-hundred day simple moving average of $5.36. The firm has a market capitalization of $27.75 million, a price-to-earnings ratio of -1.15 and a beta of 1.45. Pluri has a 52 week low of $3.45 and a 52 week high of $8.56.

Pluri (NASDAQ:PLUR) last released its quarterly earnings results on Monday, February 12th. The company reported ($0.96) earnings per share (EPS) for the quarter. The firm had revenue of $0.11 million for the quarter. Pluri had a negative net margin of 6,708.40% and a negative return on equity of 177.94%.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.